Renal allograft survival in outbred mongrel dogs using rabbit anti-dog thymocyte serum in combination with immunosuppressive drug therapy with or without donor bone marrow.
Therapeutic renal transplantation in dogs is currently being investigated as a treatment for endstage renal disease. This pilot study examines the effect of donor bone marrow (DBM) infusion and antithymocyte serum (ATS) in combination with immunosuppressive drug therapy in prolonging renal allograft survival in dogs. Seven normal outbred mongrel dogs received an unmatched renal allograft. All dogs received rabbit anti-dog thymocyte serum (RADTS), prednisone (Pr), cyclosporine-A (CsA) and azathioprine (Aza). In addition, three dogs (group 1 test) received DBM and four dogs (group 2 control) did not receive DBM. Serum CsA levels were measured throughout the study. Immunosuppressive therapy was gradually reduced with Pr, CsA, and Aza withdrawn at 200, 450, and 680 days, respectively. Allograft rejection was treated with prednisolone sodium succinate. One dog in group 1 and one in group 2 died as a result of infectious canine rhinotracheitis and rejection early in the study. Renal allograft torsion occurred in one group 1 dog. The remaining four dogs survived the 2 years of the study. The dogs in group 2 (three dogs) all rejected the renal allograft after total drug withdrawal, the surviving dog in group 1 did not. This study demonstrates that RADTS, Pr, CsA, and Aza in combination can prolong renal allograft survival in mongrel dogs, whereas DBM may enhance the unresponsive state.
Department of Clinical Studies, Ontario Veterinary College, University of Guelph.
K A
KA
Mathews
D L
DL
Holmberg
K
K
Johnston
C M
CM
Miller
A G
AG
Binnington
G
G
Maxie
M
M
Atilola
G
G
Smith
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000662:veterinary*; D016572:Cyclosporine / Q000627:therapeutic use; D004285:Dogs / Q000601:surgery*; D005260:Female; D006084:Graft Rejection / Q000188:drug therapy; D006085:Graft Survival; D007165:Immunosuppression Therapy / Q000662:veterinary*; D007518:Isoantibodies / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000662:veterinary*; D008297:Male; D010865:Pilot Projects; D011182:Postoperative Care / Q000662:veterinary; D011183:Postoperative Complications / Q000662:veterinary; D011239:Prednisolone / Q000031:analogs & derivatives / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000276:immunology; D014184:Transplantation, Homologous / Q000662:veterinary
D000911:Antibodies, Monoclonal; D007518:Isoantibodies; C035678:anti-Thy antibody; D016572:Cyclosporine; D011239:Prednisolone; C021322:prednisolone hemisuccinate; D001379:Azathioprine; D011241:Prednisone